Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

EarlySense Patient Monitoring System Saw 40 Percent Increase in Adoption in 2016

XTALKS VITALS NEWS

Patient

The contact-free system was used to monitor the vital signs of over 115,000 patients in hospital facilities and home environments last year.

Share this!

January 25, 2017 | by Sarah Hand, M.Sc.

In 2016, adoption of the EarlySense continuous medical monitoring system increased by almost 40 percent, to include over 105 clinical care areas around the world. The contact-free system was used to monitor the vital signs of over 115,000 patients in hospital facilities and home environments last year.

According to statistically analysis conducted by EarlySense, the company estimates that their monitoring system may have helped save more than 550 lives, and prevent 800 falls and over 45,000 hospitalization days. In the absence of EarlySense monitoring and alerts, these events would cost a combined $30 million.

“In 2016, EarlySense significantly expanded the reach and impact of our hospital-proven technology and we are pleased to achieve these milestones,” said Avner Halperin, Founder and CEO of EarlySense. “Almost daily we hear from medical institutions about how they saved a life or dramatically improved a patient's outcome by leveraging EarlySense – it is extremely rewarding. It is clear that continuous monitoring is poised to become a global standard of care, and we look forward to providing valuable health insight and support to facilities, health teams and patients in 2017 and beyond.”



EarlySense has since made some upgrades to it continuous monitoring medical devices. The company launched InSight, a product aimed at reducing patient falls and hospital admissions in nursing facilities. A new Multi-Parameter Alert was also introduced, which monitors a patient’s heart and breathing rates to help healthcare providers in the early detection of sepsis.

“Non-ICU patients are at risk for a variety of complications during hospitalization and early warning signs are often subtle and not easily detected,” said Halperin. “By providing healthcare professionals with continuous data and timely indication of change through our Multi-Parameter Alert, precious time can be saved enabling early detection and treatment of sepsis as well as other potential adverse events.”

EarlySense is also breaking into the consumer health space by introducing its LIVE health monitoring solution. LIVE is primarily a sleep monitor, which EarlySense claims is the first consumer health monitoring product to be based on medically-proven technology.


Keywords: Patient Monitoring, Medical Device, Healthcare


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News


New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News


Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases


Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects


Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance


Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned


Copyright © 2016-2017 Honeycomb Worldwide Inc.